CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024.
開曼註冊的生物製藥公司CASI製藥公司（納斯達克股票代碼：CASI）今天宣佈，任命醫學博士丹尼爾·朗爲首席財務官兼高級副總裁，自2024年7月8日起生效。
Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform.
郎博士擁有超過30年的醫師科學家、投資者和生物技術高管經驗。他是一名受過加州大學舊金山分校培訓的心臟病專家，隨後在法拉隆資本擔任投資組合經理和RS Investments Value Group首席投資官擁有20年的投資經驗。最近，他曾擔任Athenex細胞療法部門的總裁，領導了nkT細胞平台的臨床開發。